BLAINVILLE, Quebec (CANADA), June 20, 2016 – Last January, Blainville-based pharmaceutical company Duchesnay became a Major Partner of la Fondation OLO. Under their two-year partnership, Duchesnay provides pregnant women living below the poverty line with its PregVit® and PregVit® Folic 5 prenatal vitamins free of charge.
Duchesnay’s primary mission is to improve women’s quality of life throughout pregnancy and breastfeeding, while reducing the risks of birth defects for their unborn babies. La Fondation OLO’s mission is to provide for the nutritional needs of vulnerable pregnant women. The similarity between the two organizations’ vocations made this partnership a “natural marriage”, as noted by OLO spokesperson Pierre-François Legendre during his recent visit to Duchesnay.
Legendre, along with fellow actor and OLO spokesperson Hélène Bourgeois-Leclerc, were attending a reception at the company’s headquarters, where the “Diamond Spoon” plaque presented to Duchesnay in recognition of its support was presented to the company’s employees.
“We are very proud to be a Major Partner of la Fondation OLO, with whom we share an unwavering commitment to the well-being of expectant mothers and their unborn children. We look forward to continuing our partnership over the next two years”, affirmed Carole Boyer, Vice President Corporate Affairs and Communications at Duchesnay.
About PregVit®
PregVit® and Pregvit® folic 5 are preconception, prenatal and postpartum supplements. The aim of their unique formulation and twice-daily dosing (morning and night) is to optimize the absorption of the nutrients that are most important during pregnancy and breastfeeding. PregVit® and Pregvit® folic 5 are available by prescription only. Women who are planning to become pregnant are advised to talk to their healthcare provider to determine whether PregVit® or Pregvit® folic 5 is right for them.
About Duchesnay
Duchesnay Inc. is a unique Quebec-based pharmaceutical company dedicated to the health and quality of life of pregnant women and their unborn babies. To that end, the company works to advance maternal-fetal medicine to reduce the risks of birth defects and to develop safe and effective pharmaceutical solutions for use during pregnancy and breastfeeding. To learn more about Duchesnay, visit us at www.duchesnay.com
